Invokana contains canagliflozin and is used for type 2 diabetes. It also has specific heart and kidney uses in certain adults with type 2 diabetes, alongside precautions about foot health and other risks.
The approved uses and formulations described here follow US prescribing information. They may differ in other countries.
| Medicine detail | Details |
|---|---|
| Active ingredient(s) | canagliflozin |
| Medicine class | SGLT2 inhibitor |
| Forms and strengths | Oral tablets: 100 and 300 mg |
Who the US label covers
Current US labeling includes glucose control in type 2 diabetes from age 10. It also includes cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease, and specified kidney and cardiovascular outcomes in adults with type 2 diabetes and diabetic nephropathy with albuminuria above the labeled threshold.
Source: [1]
Choosing the appropriate strength
Invokana tablets contain 100 or 300 mg. Kidney function and the reason for treatment help determine the prescribed dose. Its kidney indication applies to a specified group of people with type 2 diabetes and diabetic nephropathy, rather than to every kind of kidney disease.
Source: [1]
Foot problems need attention
Lower-limb amputation remains a warning in the prescribing information. Tell the clinical team about prior amputation, poor circulation, neuropathy, ulcers or new foot infection. Removal of a historical boxed warning should not be interpreted as removal of all amputation-related precautions.
Source: [1]
Other important risks
Canagliflozin can be associated with ketoacidosis, volume depletion and genital or urinary infections. Serious symptoms during illness or fasting need assessment, even without very high glucose. A clinician should explain any temporary interruption needed around surgery or prolonged fasting.
Source: [1]
Distinguishing related products
Invokamet adds metformin and carries additional restrictions and a lactic-acidosis boxed warning. Other SGLT2 inhibitors have their own evidence and indications. A class relationship is useful context, but it is not a basis for assuming identical outcomes or a direct substitution.
Source: [1]
Questions and answers
Is Invokana the same as Invokamet?
No. Invokamet includes metformin as a second ingredient.
Did removal of the amputation boxed warning remove the precaution?
No. Lower-limb amputation remains a warning in the current prescribing information.
Does Invokana treat every kind of chronic kidney disease?
No. Its kidney indication applies to specified people with type 2 diabetes and diabetic nephropathy. It is not approved for every type of kidney disease.
Related reading
Sources
Sources checked 1 October 2026. This information does not replace advice from your healthcare professional. For complete warnings and instructions, read the product information and consult the prescribing team.
Reviewed by: Mattias Hagman, PhD
About the reviewer:
Dr Mattias Hagman (PhD, University of Sydney) has an academic background and experience working with healthcare-related content and regulated industries. He has lecturing experience at international universities, including Stockholm University and the University of Malta.
Last reviewed: October 2026